TABLE 2.
Outcome of treatment in all patients and in patients infected with a nalidixic acid-resistant isolate
| Parameter(s) | Treatment
|
P | |
|---|---|---|---|
| Ofloxacin | Azithromycin | ||
| All patients (n) | 44 | 44 | |
| Clinical failures (n [%]) | 6 (13.6) | 2 (4.5) | 0.27 |
| Persistent fever and symptoms | 3 (6.8) | 1 (2.3) | |
| Gastrointestinal hemorrhage | 1 (2.3) | 1 (2.3) | |
| Relapse | 2 (4.5) | 0 | |
| Microbiological failures (n [%]) | 2 (4.5) | 1 (2.3) | 1.00 |
| Mean fever clearance time (h) (95% CI, range) | 134 (111–156, 12–264) | 130 (118–142, 60–204) | 0.19 |
| Mean duration (days) of hospitalization after starting treatment (95% CI, range) | 10.5 (9.5–11.5, 5–20) | 9.6 (8.9–10.3, 7–19) | 0.05 |
| Patients infected with nalidixic acid-resistant isolate (n) | 21 | 25 | |
| Clinical failures (n [%]) | 4 (19.0) | 1 (4.0) | 0.16 |
| Persistent fever and symptoms | 3 (14.3) | 0 | |
| Gastrointestinal hemorrhage | 0 | 1 (4.0) | |
| Relapse | 1 (4.8) | 0 | |
| Microbiological failures (n [%]) | 1 (4.8) | 0 | 0.46 |
| Mean fever clearance time (h) (95% CI, range) | 174 (143–205, 60–264) | 135 (119–151, 72–186) | 0.004 |
| Mean duration (days) of hospitalization after starting treatment (95% CI, range) | 11.9 (10.4–13.5, 7–20) | 9.3 (8.5–10.0, 7–14) | 0.001 |